Navigation Links
Vivakor Confirms Record Date of Stock Dividend

CORALVILLE, Iowa, Dec. 4 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today confirmed that its shareholders of record on December 1, 2009 will receive the dividend of shares of common stock of HealthAmerica, Inc. that was previously approved by Vivakor's Board of Directors. HealthAmerica is a private Nevada corporation of which Vivakor owned approximately 84% of the outstanding common shares on the record date. The distribution date is still expected to be December 9, 2009. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on December 1, 2009. After the dividend distribution, Vivakor will continue to own approximately 62% of the outstanding common stock of HealthAmerica.

Vivakor shareholders will not be required to take any action to receive the HealthAmerica common shares on the distribution date.

About Vivakor, Inc.

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at

About HealthAmerica, Inc.

HealthAmerica is developing a patented, FDA 510(k) cleared, technology (VIVASlices(TM) that is expected to enhance the resolution of images resulting from MRI. The underlying algorithm may also be useful in determining blood flow velocity measures in imaged tissues, which would be valuable in accessing areas of blood flow constriction from plaques or other hematologic deposits. This information could help physicians better diagnose, predict and assess stroke and related diseases involving blood flow obstruction.

At the end of 2000, there were approximately 9,500 MRI (magnetic resonance imaging) systems installed worldwide. While changes in medical reimbursements have slowed the sale of new machines, there is an increased demand for improved efficiency (i.e. accelerated patient throughput) from current systems. Additionally, intense competition between various medical facilities and the rapid distribution of new advances in imaging (such as MR angiographies, which allow evaluation of blood vessels without any invasive procedure) puts additional pressure on MRI because increased image quality requires additional time. Thus there is a huge need for an application like VIVASlices that can improve both throughput and image quality.


This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's and HealthAmerica's products and markets. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

    Vivakor, Inc.
    Matt Nicosia, 319-625-2172

SOURCE Vivakor, Inc.

SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vivakor, Inc. Announces Stock Dividend
2. New study confirms exotic electric properties of graphene
3. Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products
4. Analysis confirms that nano-related research has strong multidisciplinary roots
5. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
6. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
7. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
8. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
9. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
10. GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
11. Mylan Confirms Four First-to-File Challenges
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):